Synthetic lethality in PTEN-mutant prostate cancer is induced by combinatorial PI3K/Akt and BCL-XL inhibition

Molecular Cancer Research

Volumn 14, Issue 12, 2016, Pages 1176-1181

  Ren, Wenying ^a   Joshi, Raghav ^a   Mathew, Paul ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 1210477; A 1331852; ALPHA5 INTEGRIN; BUPARLISIB; IPATASERTIB; NAVITOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN MCL 1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VENETOCLAX; 2-(4-CHLOROPHENYL)-1-(4-(7-HYDROXY-5-METHYL-6,7-DIHYDRO-5H-CYCLOPENTA(D)PYRIMIDIN-4-YL)PIPERAZIN-1-YL)-3-(ISOPROPYLAMINO)PROPAN-1-ONE; AMINOPYRIDINE DERIVATIVE; ANILINE DERIVATIVE; BCL2L1 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; NVP-BKM120; PIPERAZINE DERIVATIVE; PROTEIN BCL X; PTEN PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL ADHESION; CONTROLLED STUDY; DRUG POTENTIATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; LETHAL MUTATION; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

AMINOPYRIDINES; ANILINE COMPOUNDS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG THERAPY, COMBINATION; HUMANS; INTEGRIN ALPHA5; MALE; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERAZINES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; SULFONAMIDES; SYNTHETIC LETHAL MUTATIONS;

EID: 85003876125     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0202     Document Type: Article

References (20)

1. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
2. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841-6.
3. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466:829-34.
4. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011;121:1298-312.
5. Joshi R, Goihberg E, Ren W, Pilichowska M, Mathew P. Proteolytic fragments of fibronectin function as matrikines driving the chemotactic affinity of prostate cancer cells to human bone marrow mesenchymal stromal cells via the α5β1 integrin Cell Adhesion and Migration 2016 online: 11 Aug, Pages 1-11: http://dx.doi.org/10.1080/19336918.2016.1212139.
6. Van der Velde-Zimmermann D, Verdaasdonk MA, Rademakers LH, De Weger RA, Van den Tweel JG, Joling P. Fibronectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via alpha5 beta1 integrin. Exp Cell Res 1997;230:111-20.
7. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002;115:3729-38.
8. Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 2015;7:279ra40.
9. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999;59:241-8.
10. Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little? Cancer Res 2011;71:629-33.
11. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009;41:619-24.
12. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-4.
13. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1:E59.
14. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high gleason score and advanced stage. Cancer Res 1999;59:4291-6.
15. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28.
16. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, García-Echeverría C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 2009;106:268-73.
17. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 2014;13:1021-31.
18. Roberts MS, Woods AJ, Dale TC, Van Der Sluijs P, Norman JC. Protein kinase B/Akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. Mol Cell Biol 2004;24:1505-15.
19. King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS. Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol 1997;17:4406-18.
20. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005;8:287-97.